
The FDA approved oral venglustat for neurological manifestations of type 3 Gaucher disease after the phase 3 LEAP2MONO trial showed superiority over imiglucerase on a combined ataxia and cognition measure.
Some good news about Huntington disease: most of the behavioral symptoms can be managed with treatments developed for other conditions.






